# Sclerosis PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sclerosis

> Sclerosis, sponsored by uniQure N.V. (QURE): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | sclerosis |
| Codes | AMT-162, SPU-16 |
| Sponsor | uniQure N.V. (QURE) https://sec-api.dev/companies/qure/catalysts |
| Indications | sod1 amyotrophic lateral sclerosis |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Oct 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-02-27, last confirmed 2025-02-27.
- SEC Form 10-K (accession 0001558370-25-001699): "In October 2024, we announced the first patient was dosed in a Phase I/IIa clinical trial of AMT-162 for the treatment of SOD1-ALS." https://www.sec.gov/Archives/edgar/data/1590560/000155837025001699/qure-20241231x10k.htm

### 1H 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1/2. Indication: SOD1 amyotrophic lateral sclerosis.
- First seen 2025-02-27, last confirmed 2025-07-29.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-009692): "AMT-162 for the treatment of SOD1 amyotrophic lateral sclerosis (ALS) - The Company continues to enroll patients in the Phase I/II EPISOD1 study and expects to present initial data in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1590560/000155837025009692/qure-20250729xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007065): "The Company expects to present initial data from the study in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1590560/000155837025007065/qure-20250509xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001693): "The Company initiated enrollment in the second dose cohort in the first quarter of 2025 and expects to present initial data from the study in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/qure-20250227xex99d1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sclerosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sclerosis PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sclerosis

```bibtex
@misc{secapidev_pdufa_sclerosis_20261116,
  title        = {Sclerosis PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sclerosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sclerosis_20261116","title":"Sclerosis PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sclerosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
